Loading...

AEON AEON BIOPHARMA INC Other Situations 8-K Filing

N BP

N

AEON BIOPHARMA INC

(AEON)

2023 8-K

Investor Presentation Update

Q1 Financial Results

Delisting Notice

Financial Results Announced

Executive Changes

Equity Exchange Deal

Corporate Presentation Update

Exchange Agreement Details

Corporate Presentation Update

Q3 Financial Results

Securities Agreement Q4

Corporate Presentation Rele...

Investor Meetings

Financial Statements

Notice of Non-compliance

CEO Appointment

Management Changes

Financial Results

Corporate Presentation

Stock Split Approval

Delisting Notice

Public Offering

Pricing Announcement

Bylaw Amendment

Corporate Presentation

Financial Results

Regulation FD Disclosure

Annual Meeting of Stockholders

Resignation and Appointments

Financial Results Announcement

Preliminary Results - ABP-4...

Entry into a Material Defin...

Redemption of Public Warrants

Redemption of Warrants

Financial Results Announcement

Entry into a Material Defin...

Senior Secured Convertible ...

Restatement of Financial St...

Earnings Reports

Clinical Updates on ABP-450...

Business Combination

Investor Meetings

Merger of Equals

Arrangement for Business Co...

Business Combination Agreement

Proxy Statement for Special...

Proxy Statement for Special...

Proxy Statement for Busines...

Delisting Notice

Proxy Statement for Special...

Proxy Statement for Busines...

Proxy Statement for Busines...

Form 8-K Filing

Amendment to Business Combi...

Restatement of Financial St...

Investor Conferences

Amendment Approval

Proxy Statement for Busines...

Interim Financing

Financing Agreement

External Links:

Priveterra Acquisition Corp. filed a Form 8-K disclosing a press release by AEON Biopharma, Inc. regarding a key opinion leader webinar on migraine treatments using botulinum toxin.

AI Assistant

AEON BIOPHARMA INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.